Risk of Diabetic Retinopathy in Patients With Type 2 Diabetes After SGLT-2 Inhibitors: A Nationwide Population Cohort Study.

Autor: Huang ST; Division of Nephrology, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.; School of Medicine, China Medical University, Taichung, Taiwan., Bair PJ; School of Medicine, China Medical University, Taichung, Taiwan.; Graduate Institute of Biomedical Sciences, School of Medicine, China Medical University, Taichung, Taiwan., Chang SS; School of Medicine, China Medical University, Taichung, Taiwan.; Division of Cardiovascular Medicine, China Medical University Hospital, Taichung, Taiwan., Kao YN; Division of Nephrology, Taichung Veterans General Hospital, Taichung, Taiwan.; School of Medicine, China Medical University, Taichung, Taiwan., Chen SN; Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan., Wang IK; School of Medicine, China Medical University, Taichung, Taiwan.; Graduate Institute of Biomedical Sciences, School of Medicine, China Medical University, Taichung, Taiwan., Chiu CW; Division of Nephrology, Taichung Veterans General Hospital, Taichung, Taiwan., Chang CT; School of Medicine, China Medical University, Taichung, Taiwan., Shih YH; Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan., Li CY; Graduate Institute of Biomedical Sciences, School of Medicine, China Medical University, Taichung, Taiwan., Yu TM; Division of Nephrology, Taichung Veterans General Hospital, Taichung, Taiwan.; School of Medicine, China Medical University, Taichung, Taiwan.; Graduate Institute of Biomedical Sciences, School of Medicine, China Medical University, Taichung, Taiwan.
Jazyk: angličtina
Zdroj: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 Jan; Vol. 115 (1), pp. 95-103. Date of Electronic Publication: 2023 Oct 25.
DOI: 10.1002/cpt.3074
Abstrakt: Diabetic retinopathy (DR) accounts for 80% of cases of vision loss in patients with type 2 diabetes mellitus (T2DM). Interventional treatments are only indicated in advanced DR and are ineffective in some patients. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are used to attenuate T2DM-associated cardiovascular complications. We conducted the cohort study to investigate the effect of SGLT2is on DR development. Data (May 2016-December 2018) obtained from the Taiwan National Health Insurance Research Database were analyzed in this nationwide retrospective cohort study. After propensity score matching, a total of 31,764 patients receiving SGLT2is and another 31,764 patients receiving dipeptidyl peptidase 4 inhibitors (DPP4is) were included in this study. Multiple Cox proportional-hazards regression models were used to evaluate DR risk. Overall DR incidence among SGLT2i or DPP4i users was 10.9 or 15.6 per 10,000 patient-years, respectively. After covariate adjustment, DR (both early and late stage) risk was substantially lower in SGLT2i users (adjusted hazard ratio: 0.68, 95% confidence interval: 0.6-0.78) than in DPP4i users. DR risk appears to be considerably lower in SGLT2i users than in DPP4i users. Glycemic control measurement with HbA1C level was unavailable in this claim database.
(© 2023 The Authors. Clinical Pharmacology & Therapeutics © 2023 American Society for Clinical Pharmacology and Therapeutics.)
Databáze: MEDLINE
Externí odkaz: